Variable
|
Study 1a
|
Study 2b
|
---|
N (%)
|
N (%)
|
---|
H3N2_A + vec
|
15 (18.5)
|
66 (88.0)
|
H3N2_B +vec
|
49 (60.5)
|
72 (96.0)
|
H3N2_C +vec
|
39 (48.1)
|
61 (81.3)
|
H3N2_home +ved
|
60 (74.1)
|
67 (89.3)
|
H1N2 +vee
|
43 (53.1)
|
62 (82.8)
|
H1N1_C +vef
|
7 (8.6)
|
14 (18.7)
|
H1N1_P +veg
|
15 (18.5)
|
24 (32.0)
|
H1N1_home +ved
|
42 (51.8)
|
22 (29.3)
|
Cluster_H3N2_Heterologoush
|
Cluster 1 (low heterologous)
|
65 (80.2)
|
45 (60.0)
|
Cluster 2 (high heterologous)
|
16 (19.7)
|
24 (32.0)
|
Cluster 3 (high heterologous)
|
–
|
6 (8.0)
|
PRRSV +vei
|
25 (30.9)
|
14 (18.7)
|
Mhyo +vej
|
67 (82.7)
|
64 (85.3)
|
Female
|
52 (65.8)
|
37 (49.4)
|
Male
|
27 (34.2)
|
38 (50.7)
|
Room5
|
45 (55.6)
|
30 (40.0)
|
Room6
|
9 (11.1)
|
30 (40.0)
|
Room7
|
27 (33.3)
|
15 (20.0)
|
-
a,bTwo distinct longitudinal studies were performed in nursery pigs.
-
cDifferent H3N2 variants broadly classified into cluster 4 of H3N2 swine influenza A virus and isolated in Ontario in 2012 and used in the hemagglutination inhibition assay.
-
dH3N2 and H1N1 viruses detected in the study and used as antigens in the hemagglutination inhibition assay.
-
eH1N2 with hemagglutinin of the 2009 pandemic lineage and neuraminidase of the Cluster 4 H3N2 IAV-S.
-
fH1N1 influenza A virus (IAV-S) broadly classified as the classical swine H1N1 virus used in hemagglutination inhibition assay.
-
gH1N1 influenza A virus (IAV-S) of the 2009 H1N1 pandemic lineage used in hemagglutination inhibition assay.
-
hGroupings based on cluster analysis of maternally derived antibodies for heterologous strains of H3N2 viruses (labeled here withc).
-
iPositive for maternally derived antibodies for PRRSV.
-
jPositive for maternally derived antibodies for Mycoplasma hyopneumoniae.